It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share ...

Coral Gables, FL-based Catalyst Pharmaceuticals , Inc. (NASDAQ:CPRX), a $2.69 billion market cap biopharmaceutical company that has delivered an impressive 54% return to shareholders over the past ...

Emcure Pharmaceuticals Limited, one of India's leading pharma companies announced the inauguration of its state-of-the-art Formulation Research and Development (R&D) Centre near Tapovan Circle, ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

This was the stock's second consecutive day of losses.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most ...

A group of researchers have analyzed thousands of reports from the past decade, identifying a tin-based catalyst that aids the production of formic acid, an indispensable chemical in various ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 11.63% ...

Oppenheimer reaffirmed its positive stance on Catalyst Pharmaceutical (TADAWUL:2070) Partners (NASDAQ:CPRX), maintaining an ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...